Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41748

Title:	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Authors:	Paz-Ares, L Tan, E-H O'Byrne, K Zhang, L Hirsh, V Boyer, M Yang, J C-H Mok, T Lee, K H Lu, S Shi, Y Lee, D H Laskin, J Kim, D-W Laurie, S A Kölbeck, K Fan, J Dodd, N Märten, A Park, K View more
Keywords:	NSCLC afatinib gefitinib overall survival View more
Mesh:	Afatinib Aged Antineoplastic Agents Carcinoma, Non-Small-Cell Lung ErbB Receptors Female Gefitinib Humans Kaplan-Meier Estimate Lung Neoplasms Male Middle Aged Mutation Proportional Hazards Models Quinazolines Treatment Outcome View more
Issue Date:	2017
Citation:	Ann. Oncol..2017 02;(28)2:270-277
Abstract:	In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Here, we present primary analysis of mature overall survival (OS) data.
PMID:	28426106
URI:	https://hdl.handle.net/20.500.12530/41748
Rights:	openAccess
Appears in Collections:	Hospitales > H. U. 12 de Octubre > Artículos

Files in This Item:

File	Description	Size	Format
PMC5391700.pdf		398.77 kB	Adobe PDF	View/Open